RTI Surgical ("RTI" or "the Company"), a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine, announced today it has successfully ...

REFRaME-P1 is a registration-enabling study evaluating the efficacy and safety of luvelta in infants and children under 12 years of age with CBF/GLIS AML. This will be a global study, with the ...

Third Quarter 2024 Financial Results Cash, cash equivalents, and investments as of September 30, 2024, were approximately $19.7 million. The Company anticipates that its cash, cash equivalents and ...

Total cost of revenue was $7.0 million in the third quarter of 2024, a decrease of 10% compared to $7.8 million in the third quarter of 2023. Gross margin was positive $0.6 million, or positive 8%, ...

Depuis le début de notre partenariat en 2016, Pink in the City, qui a lancé l’événement Raise Craze, a recueilli plus d’un million de dollars pour la Fondation du CUSM. Ces fonds ont joué un rôle ...

Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on October 31, 2024, notifying the Company ...

Novo Nordisk expects to file for regulatory approvals in the US and EU in the first half of 2025. The detailed results from ESSENCE will be presented at a scientific conference in 2024. Part 2 of the ...

The pace of enrollment in our NEUTRALIZE-AKI trial has quickly accelerated, with 14 new subjects enrolled in slightly more than six weeks,” said Kevin Chung, MD, Chief Medical Officer of SeaStar ...

This strategic move into the Chicagoland market represents a key step in Safety Shot's nationwide expansion strategy. By partnering with these regional grocery chains renowned for their commitment to ...

Since the beginning of the partnership in 2016, Pink in the City, which began Raise Craze, has raised over $1 million for the MUHC Foundation. These funds have been instrumental in advancing breast ...

The anticipated impact of Merit’s acquisition of Cook Medical’s lead management portfolio on Merit’s operating and financial performance for 2024 and thereafter was disclosed in Merit’s October 30, ...

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.